Safety and efficacy of a feed additive consisting of l‐tryptophan produced using Corynebacterium glutamicum KCCM 80346 for all animal species (CJ Europe GmbH) Authors: EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP), Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Ilen Röhe, Katerina Theodoridou, Jürgen Gropp, Montserrat Anguita, Nicole Bozzi Cionci, Matteo L. Innocenti, Elisa Pettenati, Joana Revez, Joana P. Firmino Published: 2025 ABSTRACT AbstractFollowing a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of L‐tryptophan produced by fermentation using the genetically modified strain of Corynebacterium glutamicum, KCCM 80346, as a nutritional additive in feed for all animal species and categories. In the manufacturing process used to obtain the product under assessment, the cells from the production strain are inactivated but not removed from the final product. The FEEDAP Panel concluded that the additive does not give rise to any safety concern regarding the genetic modification of the strain. DNA from the strain is present in the final product, but its presence does not raise any safety issue since the strain does not harbour any gene of concern. No viable cells of the strain were detected in the final product. The use of l‐tryptophan produced using C. glutamicum KCCM 80346 in feed is considered safe for non‐ruminant species. There may be a risk for an increased production of toxic metabolites when unprotected tryptophan is used in ruminants. The use of the additive in animal nutrition is considered safe for the consumers of products from animals receiving the additive, and to the environment. With regard to the safety for the user, the additive is not irritant to the eyes or skin, but it should be considered a skin and respiratory sensitiser. Exposure by inhalation and dermal routes is considered a risk. The additive l‐tryptophan produced using C. glutamicum KCCM 80346 is regarded as an effective source of the amino acid l‐tryptophan for all non‐ruminant species. To be as efficacious in ruminants as in non‐ruminants, it should be protected from ruminal degradation. INTRODUCTION Background and Terms of Reference Regulation (EC) No 1831/2003 1 establishes the rules governing the Community authorisation of additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any person seeking authorisation for a feed additive or for a new use of feed additive shall submit an application in accordance with Article 7. The European Commission received a request from CJ Europe GmbH 2 for the authorisation of the additive consisting of l‐tryptophan produced using the genetically modified strain of Corynebacterium glutamicum, KCCM 80346, when used as a feed additive for all animal species (category: nutritional additives; functional group: amino acids, their salts and analogues). According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the application to the European Food Safety Authority (EFSA) as an application under Article 4(1) (authorisation of a feed additive or new use of a feed additive). The dossier was received on 28 December 2022 and the general information and supporting documentation are available at https://open.efsa.europa.eu/questions/EFSA‐Q‐2022‐00882. The particulars and documents in support of the application were considered valid by EFSA as of 2 October 2023. According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and documents submitted by the applicant, shall undertake an assessment in order to determine whether the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the safety for the target animals, consumer, user and the environment and on the efficacy of the feed additive consisting of l‐tryptophan produced using C. glutamicum KCCM 80346, when used under the proposed conditions of use (see Section 3.1.4 ). Additional information The additive consists of a l‐tryptophan produced using the genetically modified C. glutamicum KCCM 80346, intended to be used as a nutritional additive (functional group: amino acids, their salts and analogues) in feed for all animal species. It has not been previously authorised as a feed additive in the European Union. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) issued a scientific opinion on the safety and efficacy of l‐tryptophan produced with C. glutamicum KCCM 80346 for all animal species (EFSA FEEDAP Panel, 2025). DATA AND METHODOLOGIES Data The present assessment is based on data submitted by the applicant in the form of a technical dossier 3 in support of the authorisation request for the use of l‐tryptophan produced using C. glutamicum KCCM 80346 as a feed additive. In accordance with Article 38 of the Regulation (EC) No 178/2002 4 and taking into account the protection of confidential information and of personal data in accordance with Articles 39 to 39e of the same Regulation, and of the Decision of EFSA's Executive Director laying down practical arrangements concerning transparency and confidentiality, 5 a non‐confidential version of the dossier has been published on Open.EFSA. According to Article 32c(2) of Regulation (EC) No 178/2002 and to the Decision of EFSA's Executive Director laying down the practical arrangements on pre‐submission phase and public consultations, EFSA carried out a public consultation on the non‐confidential version of the technical dossier from 7 March to 28 March 2024 for which no comments were received. The confidential version of the technical dossier was subject to a target consultation of the interested Member States from 3 October 2023 to 3 January 2024; the comments received were considered for the assessment. The FEEDAP Panel used the data provided by the applicant together with data from other sources, such as previous risk assessments by EFSA or other expert bodies, peer‐reviewed scientific papers, other scientific reports and experts' knowledge, to deliver the present output. EFSA has verified the European Union Reference Laboratory (EURL) report as it relates to the methods used for the control of the L‐tryptophan produced using C. glutamicum KCCM 80346 in animal feed. 6 Methodologies The approach followed by the FEEDAP Panel to assess the safety and the efficacy of l‐tryptophan produced using C. glutamicum KCCM 80346 is in line with the principles laid down in Regulation (EC) No 429/2008 7 and the relevant guidance documents: Guidance on the assessment of the safety of feed additives for the consumer (EFSA FEEDAP Panel, 2017a), Guidance on the identity, characterisation and conditions of use of feed additives (EFSA FEEDAP Panel, 2017b), Guidance on the assessment of the safety of feed additives for the target species (EFSA FEEDAP Panel, 2017c), Guidance on the characterisation of microorganisms used as feed additives or as production organisms (EFSA FEEDAP Panel, 2018), Guidance on the assessment of the safety of feed additives for the environment (EFSA FEEDAP Panel, 2019), Guidance on the assessment of the safety of feed additives for the users (EFSA FEEDAP Panel, 2023), EFSA statement on the requirements for whole genome sequence analysis of microorganisms intentionally used in the food chain (EFSA, 2024) and Guidance on the assessment of the efficacy of feed additives (EFSA FEEDAP Panel, 2024). ASSESSMENT The subject of the assessment is a l‐tryptophan produced using the genetically modified C. glutamicum KCCM 80346. In the manufacturing process used to obtain the product under assessment, the cells of the production strain are inactivated but not removed from the final product. The additive is intended to be used as a nutritional additive (functional group: amino acids, their salts and analogues) in feed for all animal species. Characterisation Manufacturing process l‐Tryptophan is produced by fermentation using C. glutamicum KCCM 80346. 8 ■■■■■. 9 ■■■■■ The applicant declared that no antimicrobials are used in the manufacturing process. 10 Characterisation of the strain C. Glutamicum KCCM 80346 l‐Tryptophan is produced using a genetically modified strain of C. glutamicum, which is deposited at the Korean Culture Collection of Microorganisms (KCCM) with the accession number KCCM 80346. 11 The taxonomic identification of KCCM 80346 was confirmed by ■■■■■ 12 ■■■■■. 13 ■■■■■. 14 The susceptibility of KCCM 80346 to relevant antibiotics was tested against the list of antimicrobials described for ‘Corynebacterium and other Gram‐positive’ recommended by the FEEDAP Panel (EFSA FEEDAP Panel, 2018). 15 All measured minimum inhibitory concentration were equal to or fell below the cut off values and, therefore, the strain is considered susceptible to the relevant antibiotics. The WGS data of the strain were searched for the presence of antimicrobial resistance (AMR) genes in two databases, ■■■■■. The search resulted in ■■■■■ the EFSA thresholds (EFSA, 2024), ■■■■■. 16 Further analysis 17 ■■■■■ following EFSA's criteria (EFSA BIOHAZ Panel, 2023) ■■■■■ and therefore, it can be concluded that no acquired AMR genes were identified and the strain raises no safety concerns. Information related to the genetically modified microorganism Characterisation of the recipient or parental microorganism ■■■■■. 18 Description of the genetic modification ■■■■■. 19 ■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ ■■■■■ All the genetic modifications, including the intended and unintended ones, were reported and no concerns were identified. 20 ■■■■■ (see Section 3.1.2 ). In the context of this opinion, C. glutamicum KCCM 80346 is used for the production of a l‐tryptophan for which the cells of the production strain are inactivated but not removed from the final product. The FEEDAP Panel considers that the stability of the genetic traits as well as their rate and level of expression are not relevant for a product with non‐viable cells. The level of expression of the new genetic trait is only relevant with respect to the l‐tryptophan concentration in the final product, as described in Section 3.1.3 . Characterisation of the additive l‐Tryptophan (International Union of Pure and Applied Chemistry [IUPAC] name: (2S)‐2‐amino‐3‐(1H‐indol‐3‐yl) propanoic acid, synonyms: (S)‐α‐amino‐1‐H‐indole‐3‐propanoic acid, l‐α‐aminoindole‐3‐propionic acid, l‐α‐amino‐3‐indolepropionic acid, 2‐amino‐3‐indolylpropanoic acid, l‐β‐3‐indolylalanine), a compound identified by Chemical Abstracts Service (CAS) No 73‐22‐3 and European Inventory of Existing Commercial Chemical Substances (EINECS) No 200‐795‐6, has a molecular weight of 204.23 g/mol; the molecular formula is C11H12N2O2 and its structural formula is given in Figure 1. Molecular structure of l‐tryptophan. The additive is a l‐tryptophan produced using C. glutamicum KCCM 80346, for which the cells of the production strain are inactivated but not removed from the final product, and it is specified to contain ≥ 60% l‐tryptophan on dry matter (DM) basis and ≤ 5% moisture. 21 Table 1 shows the results of the different compositional analysis, and Table 2 shows the amino acid profile, mineral content and trace elements in five independent batches of the additive. 22 The results showed an average of 63.8% tryptophan (63.5%–64.4%) on DM basis. ■■■■■ 23 TABLE 1Results of analysis to determine the composition of the additive (%, as is, five batches).AverageRangeTryptophan (free, %)62.862.6–63.4Moisture (%)1.51.4–1.6Ash (%)7.86.0–9.0Nitrogen (%)10.9Crude fat (%)3.43.0–4.2Crude fibre (%)< 0.5Starch (%)< 0.2Total sugars 1 (%)4.83.0–7.0Ammonium nitrogen (mg/kg)262< 200–312Abbreviation: <, means below the limit of quantification. 1 Calculated as sucrose. Results of analysis to determine the composition of the additive (%, as is, five batches). Abbreviation: <, means below the limit of quantification. Calculated as sucrose. TABLE 2Results of total amino acid profile, mineral content and trace elements of the additive (% as is, five batches).AverageRange Amino acids Tryptophan 1 59.458.6–60.0Lysine0.8680.68–1.03Methionine0.2780.26–0.30Cystine0.1240.11–0.17Threonine0.8220.75–0.93Serine0.650.63–0.68Glutamic acid2.6462.56–2.74Proline0.5920.55–0.63Glycine0.8360.80–0.88Alanine1.6021.52–1.73Valine0.9960.92–1.09Isoleucine0.7780.76–0.81Leucine1.2861.26–1.33Tyrosine0.4820.44–0.52Phenylalanine0.6280.57–0.71Arginine0.8960.85–0.95 Minerals and trace elements 2 Chloride0.130.07–0.25Calcium1.521.23–1.72Phosphorus0.470.45–0.48Phosphate 3 1.421.34–1.47Sodium0.510.45–0.58Potassium0.850.66–1.15Sulfur1.311.08–1.41Sulfate3.02.6–3.3Copper0.0004–0.0039Iron0.017–0.02Zinc0.0006–0.0010Manganese0.019–0.021Magnesium0.15–0.23 1 The lower levels observed for the total tryptophan compared with the free tryptophan levels may relate to the hydrolysis step of the method used for the total tryptophan determination. 2 Copper, iron, zinc, manganese and magnesium content were analysed in four batches of the additive. 3 Phosphorus calculated as phosphate. Results of total amino acid profile, mineral content and trace elements of the additive (% as is, five batches). The lower levels observed for the total tryptophan compared with the free tryptophan levels may relate to the hydrolysis step of the method used for the total tryptophan determination. Copper, iron, zinc, manganese and magnesium content were analysed in four batches of the additive. Phosphorus calculated as phosphate. The data provided showed compliance with the specifications set by the applicant. Based on the above analytical results, the FEEDAP Panel notes that 94.9% (as is basis, including ■■■■■) of the additive has been characterised (sum of total amino acids, moisture, ash, fat, fibre, starch and total sugars). The data provided by the applicant on the impurities 24 and physical properties 25 of the additive are reported in Table 3. Magnesium and the trace elements (copper, iron, zinc, manganese) used in the manufacturing were also analysed (Table 2). TABLE 3Data on the impurities and physical properties of L‐tryptophan produced using C. glutamicum KCCM 80346. The data presented are ranges for all parameters.ParameterRangeNo. of batches Impurities Lead (mg/kg)0.023–0.0283Mercury (mg/kg)< 0.013Cadmium (mg/kg)< 0.013Arsenic (mg/kg)0.14–0.153Dioxins and furans (upper bound) 1 PCDD/Fs (ng WHO2005‐TEQ/kg)0.0573PCDD/Fs + PCBs (ng WHO2005‐TEQ/kg)0.1163nDL‐PCBs (μg/kg)0.533■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■Mycotoxins (μg/kg)Aflatoxins (B1, G1, B2, G2)< 0.023Fumonisins (B1, B2, B3)< 503Ochratoxin A< 0.53Deoxynivalenol< 103Zearalenone< 53T‐2 Toxin< 23HT‐2 Toxin< 23Nucleotides (%)Cytidine‐5‐monophosphate< 0.0001–0.03825Guanosine‐5‐monophosphate0.00256–0.04675Uridine‐5‐monophosphate0.023–0.05845Inosine‐5‐monophosphate< 0.0001–0.1245Adenosine‐5‐monophosphate0.00504–0.0635Organic acids (%)Citric acid< 0.00045Malic acid< 0.00065Succinic acid< 0.0008–0.165Lactic acid< 0.00025Formic acid< 0.0006–0.165Acetic acid< 0.001–0.045Biogenic amines (mg/kg)2‐Phenylethylamine< 1–5.985Histamine< 1–4.385Tryptamine8260–11,7005Tyramine38.3–58.65Cadaverine12.8–5605Putrescine< 15Spermidine< 15Spermine< 15■■■■■■■■■■3 Microbial contamination Salmonella spp. (per 25 g)Not detected3 Enterobacteriaceae (per 10 g)Not detected3 Escherichia coli (per 10 g)Not detected3Yeast and moulds (CFU/g)< 1003 Physical properties Physical formLight to dark brown granulesBulk density (kg/m3)625–6333Dusting potential (Stauber Heubach) (mg/m3)40–653Particle size distribution (laser diffraction) (% of particles below, v/v)3100 μm1.3–2.050 μm1.1–1.310 μm1.0 Shelf‐life (% losses) 25°C/60% RH 3 months0.0–1.4340°C/75% RH 6 months0.0–0.53 Stability in premixtures (% losses) Chicken for fattening, 25°C/60% 6 months0.0–3.33 Stability in feed (% losses) Chicken for fattening, Mash feed, 25°C/60% RH 3 months0.2–8.03Chicken for fattening, Pelleted feed, 25°C/60% RH 3 months0.0–8.03Pelleting 72–73°C0.0–3.6 Homogeneity (coefficient of variation, %) Premixture2.91Mash feed4.21Pelleted feed4.61 Note: <, means below the limit of quantification (LOQ), except for ■■■■■ and organic acids, which are below the limit of detection (LOD)Abbreviations: nDL‐PCBs, non‐dioxin‐like PCBs; PCBs, polychlorinated biphenyls; PCDDs, polychlorinated dibenzo‐p‐dioxins; PCDFs, polychlorinated dibenzofurans; TEQ, toxic equivalent factors for dioxins, furans and dioxin‐like PCBs established by WHO in 2005 (Van den Berg et al., 2006); WHO, World Health Organization. 1 Upper bound concentrations are calculated on the assumption that all values of the different congeners below the limit of quantification are equal to the limit of quantification. Values are expressed per kg of additive with 88% dry matter content. Data on the impurities and physical properties of L‐tryptophan produced using C. glutamicum KCCM 80346. The data presented are ranges for all parameters. Note: <, means below the limit of quantification (LOQ), except for ■■■■■ and organic acids, which are below the limit of detection (LOD) Abbreviations: nDL‐PCBs, non‐dioxin‐like PCBs; PCBs, polychlorinated biphenyls; PCDDs, polychlorinated dibenzo‐p‐dioxins; PCDFs, polychlorinated dibenzofurans; TEQ, toxic equivalent factors for dioxins, furans and dioxin‐like PCBs established by WHO in 2005 (Van den Berg et al., 2006); WHO, World Health Organization. Upper bound concentrations are calculated on the assumption that all values of the different congeners below the limit of quantification are equal to the limit of quantification. Values are expressed per kg of additive with 88% dry matter content. The FEEDAP Panel notes the high levels of biogenic amines, especially tryptamine, tyramine and cadaverine, which deserve attention during the manufacturing process. The FEEDAP Panel considers that the microbial contamination and the amounts of the detected impurities do not raise safety concerns. This includes also the residues of the ■■■■■, for which, taking into account its nature (and amount present in the additive), a separate assessment is done in Appendix A. The presence of viable cells of the strain was investigated in three batches of the final product, each batch tested in triplicate. 26 ■■■■■ No viable cells were detected. The presence of DNA of the strain was investigated in three batches of the final product tested in triplicate. 27 ■■■■■ (■■■■■), ■■■■■ DNA from the strain was detected in all the samples tested. Conditions of use l‐Tryptophan produced using C. glutamicum KCCM 80346 is intended to be used in feed for all animal species, directly or through complementary feed or premixtures. No inclusion levels have been proposed, as the requirements of l‐tryptophan, in quantitative terms, depend on the nutrient composition, in particular the amino acid composition of the un‐supplemented diet, the species, the age of the animal, the physiological state of the animal, the performance level and the environmental conditions. Safety Safety of C. glutamicum KCCM 80346 C. glutamicum KCCM 80346 is a genetically modified strain ■■■■■. The strain belongs to a species, C. glutamicum, that is included in the qualified presumption of safety (QPS) list when used for production purposes (EFSA BIOHAZ Panel, 2023). For the product under assessment, the qualifications are the safety of the genetic modification, the absence of acquired AMR genes and the absence of viable cells of the strain in the final product. The taxonomic identification of the strain KCCM 80346 was unequivocally established, the genetic modifications do not raise safety concerns and no acquired AMR genes were found. Additionally, in the current assessment, viable cells were not detected in the final product. Therefore, the strain fulfils the requirements for the QPS approach. DNA from the strain is present in the final product, but its presence does not raise any safety issues since the strain does not harbour any gene of concern. Consequently, the FEEDAP Panel concludes that the additive does not pose any safety concern regarding the genetically modified strain C. glutamicum KCCM 80346. Toxicological studies Genotoxicity studies, including mutagenicity Bacterial reverse mutation test In order to investigate the potential of L‐tryptophan produced using C. glutamicum KCCM 80346 to induce gene mutations in bacteria, an Ames test was performed according to the OECD Testing Guideline (TG) 471 and claimed Good Laboratory Practice (GLP) compliant. 28 The experiments were performed using Salmonella Typhimurium strains TA98, TA100, TA102, TA1535 and TA1537. Two independent experiments were conducted applying the plate incorporation and pre‐incubation methods, both in the presence and absence of metabolic activation. Based on the results of a preliminary experiment, the examined test concentrations were 5, 15.81, 50, 158.1, 500, 1581 and 5000 μg/plate in first and second tests, plus the concentration of 1.581 μg/plate in the second experiment. The test item was dissolved in deionised water. Appropriate positive and negative control chemicals were used, and the background mean numbers of revertant colonies were in the historical control range, except for the bacterial strain TA102 data, where the untreated and DMSO controls in one assay were slightly lower than the bottom limit of the historical control range. No toxicity and no increase in the mean number of revertant colonies were observed with any tester strain. The FEEDAP Panel concludes that the test item did not induce gene mutations in bacteria under the experimental conditions employed in this study. In vitro mammalian cell micronucleus test To investigate the potential of l‐tryptophan produced using C. glutamicum KCCM 80346 to induce chromosome damage, an in vitro micronucleus test was performed in mouse lymphoma L5178Y TK+/− 3.7.2C cell line following the OECD TG 487 and claimed GLP compliant. 29 Based on the results of a preliminary cytotoxicity test showing marked cytotoxicity at higher concentrations, L‐tryptophan produced using C. glutamicum KCCM 80346 was tested at 30, 90 and 270 μg/mL for the 3h‐treatment with metabolic activation followed by 21 h of recovery; 50, 100 and 300 μg/mL for the 3h‐treatment without metabolic activation (plus 21 h of recovery), and 10, 30 and 90 μg/mL for the long treatment (24 h) without metabolic activation. No changes in pH and osmolality were reported. At the end of the 3‐h treatment without metabolic activation, precipitation was observed at 500 and 250 μg/mL. None of the treatment concentrations caused a significant increase in the number of binucleated micronucleated cells when compared to the appropriate negative (vehicle) control value in the experiments with and without metabolic activation. Appropriate positive and negative control chemicals were used, and the results obtained confirmed that the experimental system was sensitive and valid. The negative control data were within the historical range for the spontaneous frequency of micronucleated cells. The positive controls caused significant increases in the number of binucleated micronucleated cells in the experiments with or without metabolic activation. The FEEDAP Panel concludes that the test item did not induce chromosome damage in vitro in mammalian cells under the experimental conditions employed in this study. Repeated dose toxicity studies 90‐day study In a 90‐day toxicity study, four groups of 10 animals/sex/group of Wistar Han IGS rats were administered with l‐tryptophan produced using C. glutamicum KCCM 80346 by oral gavage in distilled water (10 mL/kg bw per day) at dose levels of 0, 500, 1000 and 2000 mg/kg bw per day. The highest dose corresponds to 22,222.22 mg/kg complete feed (EFSA Scientific Committee, 2012). Additional groups of five animals/sex were allocated in the control and high dose group to investigate reversibility of findings for 4 weeks. The study was conducted according to the OECD TG 408 and claimed to be GLP compliant. 30 No test item related mortality was observed during the study. Clinical observations were limited to slight to severe salivations at all doses with salivation‐related reflexes (pedalling and ploughing) noted at ≥ 1000 mg/kg bw per day with a dose‐related incidence. They were not noted thereafter during the recovery period. There were no other treatment‐related changes in any of the measurements or observations made during the study. Based upon the results of this study, the no observed adverse effect level (NOAEL) was the maximum dose tested of 2000 mg additive/kg body weight per day. Conclusions on toxicological studies The FEEDAP Panel concludes that the additive does not raise concern for genotoxicity. Moreover, the results obtained in a sub‐chronic oral toxicity study raised no concerns regarding the product. Safety for the target species, the consumer and the environment The Panel considers that safety concerns from the use of this product would not derive from the amino acids present in the additive, provided that they are supplemented at appropriate amounts to satisfy the nutritional needs of the animals. Concerns may arise from the unidentified part of the additive, which amounts to approximately 5%, and may contain residues from the fermentation. The presence of impurities, including those from the manufacturing, was below the thresholds or of no concern (see Section 3.1.3 ). The strain and its genetic modification raised no concerns (see Section 3.2.1 ), and the toxicological studies performed with the additive under assessment identified no concerns (see Section 3.2.2 ). The l‐tryptophan requirements of the target animal species and the safety of this essential amino acid in non‐ruminant and ruminant nutrition are well known by feed formulators and available in general publications on animal nutrition. For non‐ruminant species, the FEEDAP Panel considers that the use of the additive is safe when added to supplement diets with appropriate amounts to satisfy animal requirements. The FEEDAP Panel reiterates that ruminal metabolism of unprotected l‐tryptophan may result in the production of toxic quantities of 3‐methylindole (skatole), which causes pulmonary disease (fog fever; emphysema) in cattle and goats (Hammond et al., 1979). Consequently, only a protected form of l‐tryptophan should be used in ruminants. The absorption and metabolic fate of l‐tryptophan in the organism is well known and well described in the scientific literature. The amino acid l‐tryptophan supplemented to feed will be incorporated into proteins of tissues and/or products of animal origin, and any of its potential excess will be metabolised and excreted. 1,1′‐Ethylidene‐bis‐l‐tryptophan (EBT) and 1‐methyl‐1,2,3,4‐tetrahydro‐beta‐carboline‐3‐carboxylic acid (MTCA) present in a specific brand of L‐tryptophan produced by fermentation were implicated in the eosinophilia–myalgia syndrome outbreak that occurred in humans in New Mexico in 1989 (Hertzman et al., 1990). ■■■■■ (see Section 3.1.3 ). Both compounds, formed during the biotechnological manufacturing process, do not represent a safety concern according to the European Pharmacopoeia 11th edition (2023) that established a maximum permitted content of EBT (impurity A) and the sum of all other impurities (B‐L, including MTCA) in L‐tryptophan (99%–100%) as 10 mg/kg and 390 mg/kg, respectively. Therefore, the Panel considers that the use of the additive in animal nutrition is safe for the consumer of products of animal origin. The amino acid l‐tryptophan is a physiological and natural component of animals and plants. When consumed, it will be absorbed and the non‐absorbed fraction will be incorporated into the intestinal microbial mass and excreted as such. Therefore, the use of the product l‐tryptophan produced using C. glutamicum KCCM 80346 in animal nutrition would not lead to any localised increase in the concentration in the environment. Environmental risk assessment of horizontal gene transfer for the additive, for which the cells of the production strain are inactivated but not removed from the final product, is only needed in case genes of concern (e.g. AMR genes) are present in the strain under assessment due to potential environmental selection of the encoded trait(s) after transfer. No genes of concern (e.g. AMR genes) are present in C. glutamicum KCCM 80346; therefore, no further environmental risk assessment is needed. The use of l‐tryptophan produced using C. glutamicum KCCM 80346 as a feed additive does not represent a risk to the environment. Safety for the user Based on the highest dusting potential measured (see Section 3.1.3 ), the FEEDAP Panel considers that the exposure of users through inhalation is likely. An acute inhalation study was performed following the OECD Testing Guideline (TG) 403. 31 The lethal concentration 50 (LC50) is more than 1.06 mg/L. The skin irritation potential of the additive was tested in a skin irritation study performed according to OECD TG 439, 32 which showed that the additive is not a skin irritant (UN GHS ‘No Category’). The eye irritation potential of the additive was tested in a study performed according to OECD TG 437, 33 which showed that the additive is not an eye irritant (UN GHS ‘No Category’). The skin sensitisation potential of the additive was tested in a study performed according to OECD TG 429, 34 which showed that the additive is not a skin sensitiser (UN GHS ‘No Category’). However, the FEEDAP Panel notes that the OECD test guidelines available at present are designed to assess the skin sensitisation potential of chemical substances only and that currently no validated assays for assessing the sensitisation potential of microbial‐based products are available. Therefore, considering the nature of the additive, it should be considered as a skin and respiratory sensitiser. Conclusions on safety for the user On the basis of the studies submitted, the additive l‐tryptophan produced using C. glutamicum KCCM 80346 is not irritant to skin or eyes, but should be considered as a skin and respiratory sensitiser. Exposure by inhalation and dermal routes is considered a risk. Efficacy Efficacy studies are not required for amino acids that occur naturally in plant and animal proteins. The nutritional role of the essential amino acid l‐tryptophan is well established in the scientific literature. The l‐tryptophan produced using C. glutamicum KCCM 80346 is regarded as an efficacious source of that amino acid for non‐ruminant animal species. For the supplemental l‐tryptophan to be as efficacious in ruminants as in non‐ruminant species, it would require protection against degradation in the rumen. Post‐market monitoring The FEEDAP Panel considers that there is no need for specific requirements for a post‐market monitoring plan other than those established in the Feed Hygiene Regulation 35 and Good Manufacturing Practice. CONCLUSIONS The additive is l‐tryptophan produced using the genetically modified strain C. glutamicum KCCM 80346. In the manufacturing process used to obtain the product under assessment, the cells of the production strain are inactivated but not removed from the final product. The additive was characterised up to 94.9%; therefore, the following conclusions apply only to the product obtained with the manufacturing process described in the application. Viable cells were not detected in the additive. DNA from the strain is present in the additive and is not considered of concern. Consequently, the additive does not give rise to any safety concern regarding the genetically modified strain and the additive resulting from its fermentation. The use of the additive in animal nutrition is considered safe for all animal species. However, there may be a risk in ruminants (pulmonary injury) when unprotected tryptophan is used, suggested by an increased production of the pneumotoxic metabolite 3‐methylindole (skatole). The use of l‐tryptophan produced using C. glutamicum KCCM 80346 in animal nutrition is considered safe for the consumer and for the environment. With regard to the safety for the user, the additive is not irritant to skin or eyes, but it should be considered a skin and respiratory sensitiser. Exposure by inhalation and dermal routes is considered a risk. The additive is regarded as an effective source of the essential amino acid l‐tryptophan for all animal species. However, in order to be in ruminants as efficacious as in non‐ruminants, it should be protected from ruminal degradation. ABBREVIATIONS antimicrobial resistance body weight Chemical Abstracts Service colony forming unit dry matter 1,1′‐ethylidene‐bis‐l‐tryptophan European Inventory of Existing Commercial Chemical Substances European Union Reference Laboratory EFSA Scientific Panel on Additives and Products or Substances used in Animal Feed International Union of Pure and Applied Chemistry limit of detection limit of quantification ■■■■■ 1‐methyl‐1,2,3,4‐tetrahydro‐beta‐carboline‐3‐carboxylic acid non‐dioxin‐like PCBs Organisation for Economic Co‐operation and Development polychlorinated biphenyls polychlorinated dibenzo‐p‐dioxins qualified presumption of safety relative humidity Replicative Population Doubling Toxic equivalent United Nations Globally Harmonised System of Classification and Labeling of Chemicals World Health Organization REQUESTOR European Commission QUESTION NUMBER EFSA‐Q‐2022‐00882 COPYRIGHT FOR NON‐EFSA CONTENT EFSA may include images or other content for which it does not hold copyright. In such cases, EFSA indicates the copyright holder and users should seek permission to reproduce the content from the original source. PANEL MEMBERS Roberto Edoardo Villa, Giovanna Azimonti, Eleftherios Bonos, Henrik Christensen, Mojca Durjava, Birgit Dusemund, Ronette Gehring, Boet Glandorf, Maryline Kouba, Marta López‐Alonso, Francesca Marcon, Carlo Nebbia, Alena Pechová, Miguel Prieto‐Maradona, Ilen Röhe, and Katerina Theodoridou. LEGAL NOTICE Relevant information or parts of this scientific output have been blackened in accordance with the confidentiality requests formulated by the applicant pending a decision thereon by EFSA. The full output has been shared with the European Commission, EU Member States (if applicable) and the applicant. The blackening may be subject to review once the decision on the confidentiality requests is adopted by EFSA and in case it rejects some of the confidentiality requests.